Carol H. Miao

Principal Investigator
Seattle Children's Research Institute
Seattle, Washington, United States

Presentation(s):

• OC 11.2 - In vivo correction of a severe Hemophilia A patient mutation using CRISPR base editing

  Sunday, June 23, 2024
  09:45 – 10:00 ICT

• OC 11.5 - Lipid nanoparticles encapsulating FVIII transgene as re-dosable and safe gene therapy in hemophilia A

  Sunday, June 23, 2024
  10:30 – 10:45 ICT

• PB0207 - Enhancing FVIII Gene Therapy: Noninvasive Transcutaneous Ultrasound-Mediated Gene Delivery of Human Factor VIII Plasmid in Hemophilia A Mice

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0247 - Exploring Predictive Biomarkers for inhibitor development in Hemophilia A

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0248 - Reduced immunogenicity of FVIII through O-Glycopeptide Integration

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0263 - Treatment of Canine Hemophilia A via Intraosseous Delivery of a Platelet-Specific Factor VIII-Lentiviral Vector

  Sunday, June 23, 2024
  13:45 – 14:45 ICT